Fig. 3: α-melittin-NPs as an in situ vaccine delay tumor growth and mediate systemic tumor control.
From: Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
a Treatment scheme. B16F10 cells were implanted into the left and right flanks of mice (n = 10 per group) on days 0 and 4, respectively. The mice were treated with intratumoral injections of 35 nmol melittin, α-peptide-NPs, and α-melittin-NPs (quantification was based on the peptide content) on days 7 and 9. b Representative pictures of mice treated with the scheme described above. All individuals are shown in Supplementary Fig. 10. c, d Tumor growth of the injected tumor (c) and distant tumor (d). e, f Individual tumor growth kinetics of the injected (e) and distant tumor (f). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, and ****P < 0.0001, as analyzed by one-way ANOVA with Bonferroni’s post hoc test (c, d). Source data are provided as a Source Data file.
